AbbVie announces positive results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine for high FR? expressing platinum-sensitive ovarian cancer

PICCOLO trial met its primary endpoint of objective response rate (ORR)

GSK disagrees with ruling by the Delaware State Court on Zantac (ranitidine) litigation

Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims

Bristol Myers Squibb announces Opdivo Plus Yervoy (ipilimumab) improved overall survival for patients with unresectable hepatocellular carcinoma

Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population

Bionova Scientific aims to set up new Plasmid DNA GMP facility neat Houston, US

Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025

Merck Specialities’ unique initiative to raise bladder cancer awareness

NTPC, Tata Memorial Centre launch cancer awareness initiative

The cancer screening and awareness camp will run for four months in the Mira Bhayander Region, benefiting approximately 5,000 police personnel

Sun Pharma to present results of the Phase III PIVOTAL trial of Nidlegy in melanoma at ASCO 2024

PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy

Merck inks MoU with KAIST to advance scientific collaboration

Partnership to facilitate collaborative research in academia and industry to further progress in life sciences

Central Council for Research in Ayurvedic Sciences launches ‘PRAGATI-2024’

AbbVie completes acquisition of Landos Biopharma

Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)